Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) January 26, 2026 22:00 Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA January 26, 2026 00:30 Regulatory Read more
BLA for subcutaneous formulation of Leqembi® accepted in China January 6, 2026 12:00 Regulatory Read more
